Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Enteral nutrition, also known as tube feeding, refers to any method of feeding that uses the gastrointestinal (GI) tract to deliver caloric requirements, including normal oral diet or liquid supplements. Nasoenteral, also known as nasogastric feeding tube, is placed in the stomach through the nose, whereas a jejunostomy tube is placed directly through the skin. The tube feeding formula is used in patients suffering from chronic conditions including head trauma, cancer, and stroke. Moreover, the nutrition formula helps premature infants to gain required nutrition and medications.
The global enteral nutrition market is estimated to be valued at US$ 2,635.9 million in 2020 and is expected to exhibit a CAGR of 5.8% over the forecast period (2020-2027).
Figure 1. Global Enteral Nutrition Market Share (%) in Terms of Value, By Region, 2020
Rising prevalence of chronic diseases is expected to drive the market growth over the forecast period
Enteral nutrition is recommended for patients with chronic disease conditions in order to combat the weak immune system which affect eating habits resulting in drastic weight loss. Moreover, the increasing prevalence of chronic diseases such as diabetes, chronic kidney disease, and malnutrition is expected to drive the global enteral nutrition market growth over the forecast period.
According to the International Diabetes Federation (IDF), in 2019, 463 million adults across the globe in the age group of 20 to 79 had diabetes and this is expected to reach 700 million by 2045, resulting in 51.2% increase between 2019 and 2045. As per the International Diabetes Federation (IDF), around 374 million people worldwide currently are at a higher risk of developing type 2 diabetes.
According to the Cancer Research UK report published in 2018, around 17 million new cancer cases were diagnosed in 2018 and around 9.6 million deaths occurred due to cancer in 2018.
Moreover, the rising prevalence of malnutrition is driving growth of the global enteral nutrition market. According to Feeding America 2015, around 2 million people suffer from starvation in the U.S, including 13 million children.
Enteral Nutrition Market Report Coverage
||Market Size in 2020:
||US$ 2,635.9 Mn
|Historical Data for:
||2016 to 2019
||2020 to 2027
|Forecast Period 2020 to 2027 CAGR:
||2027 Value Projection:
||US$ 3,903.7 Mn
- North America: U.S. and Canada
- Latin America: Brazil, Argentina, Mexico, Colombia, Peru, and Rest of Latin America
- Asia Pacific: Japan, China, South Korea, Vietnam, Philippines, India, Thailand, Indonesia, Malaysia, Australia, Taiwan, and Rest of Asia Pacific
- Europe, Middle East and Africa: Germany, France, Italy, U.K., Netherlands, Spain, Saudi Arabia, Russia, Egypt, South Africa, Turkey, Sweden, and Rest of Europe, Middle East and Africa
- By Product Type: Standard Enteral Nutrition, Enteral Nutrition for Chronic Illness.
- By Nutrition Type: Proteins, Carbohydrates, Multi-vitamins and Antioxidants, Amino Acid, Fibers, Minerals, Others.
- By Formulation: Powder, Liquid.
- By Patient Type: Infant (1 month to 2 years), Children (2 to 12 years), Adolescent & Adult (12 to 65 years), Geriatric (>65 years), Chronic Patient (Excluding all above in all age groups)
- By Application: Cancer, Gastrointestinal Diseases, Diabetes, Critical Care, Others.
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, E-commerce.
- By End User: Hospitals, Home Care Settings, Retirement Homes, Others.
Abbott Laboratories, Nestlé S.A., Danone S.A., Fresenius Kabi AG, Mead Johnson & Company, LLC, B. Braun Melsungen AG, Otsuka Pharmaceutical Co., Ltd, Meiji Holdings Co., Ltd., Bahrain Pharma, Bionova Lifesciences, Global Health Products Inc., Victus Inc., and Curtis Health Caps SP
- Rising prevalence of chronic diseases
- Increasing government initiatives, investments, and funding for research and development
|Restraints & Challenges:
- Side effects and complications caused by enteral feedings
- Lack of awareness regarding healthcare, diet, and proper nutrition in low and middle income economies
Figure 2. Global Enteral Nutrition Market Share (%), by Product Type, 2020
Increasing government initiatives, investments, and funding for research and development is expected to drive the market growth over the forecast period
For instance, in September 2017, the government of Tanzania launched the National Multi-sectoral Nutrition Action Plan (NMNAP) for 2016-2021 to address problems with malnutrition in the Tanzania. The Nutrition International’s Technical Assistance Program partnered with the government of Tanzania on this project.
Moreover, factors such as investments in research and development of novel medical nutritional products targeting various health conditions, as well as funding by various companies operating in nutrition industries are expected to drive the global enteral nutrition market growth over the forecast period.
For instance, in May 2020, Danone’s nutrition health arm, Nutricia, granted US$ 1.1 million for global nutrition research programme, a clinician-initiated research project in 16 countries across the world, to define guidelines for nutritional care for COVID-19 patients recovering after intensive care unit (ICU) admission.
Global Enteral Nutrition Market – Impact of Coronavirus (Covid-19) Pandemic
Following the outbreak of COVID-19 in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it a public health emergency. According to the World Health Organization’s report, the manifestation of the coronavirus (COVID-19) has resulted in more than 106 million infected individuals worldwide as of 9th February 2020.
COVID-19 can affect the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of drugs from one place to another.
Moreover, demand for enteral nutritional products has increased significantly during the pandemic, as nutrition therapy is recommended to patients affected with COVID-19 infection. It is more important to evaluate the nutrition status of the COVID-19 infected patients. According to data published by the American Society of Parenteral and Enteral Nutrition (ASPEN), all guidelines and recommendations available for clinical nutrition in critically ill patients also apply for severely ill COVID-19 patients.
Global Enteral Nutrition Market Restraint
The major factors restraining growth of the enteral nutrition market are the side effects and complications caused by enteral feedings. If a child has gastroesophageal reflux, aggressive enteral feeding may increase the risk of aspiration or vomiting. Other physical disadvantages are diarrhea, skin breakdown, or anatomic disruption. Mechanical disadvantages include a dislodged or occluded feeding tube.
Furthermore, lack of awareness regarding healthcare, diet, and proper nutrition in low and middle income economies is a major factor hampering growth of the global enteral nutrition market.
Major players operating in the global enteral nutrition market include Abbott Laboratories, Nestlé S.A., Danone S.A., Fresenius Kabi AG, Mead Johnson & Company, LLC, B. Braun Melsungen AG, Otsuka Pharmaceutical Co., Ltd, Meiji Holdings Co., Ltd., Bahrain Pharma, Bionova Lifesciences, Global Health Products Inc., Victus Inc., and Curtis Health Caps SP.